Company Introduction

Founded in 2018, Belief BioMed is aiming to become a globally leading gene therapy company by being committed to providing innovative therapies with improved efficacy for monogenic disorder diseases, age-related degenerative diseases, and certain malignant diseases through its AAV vector technology from early discovery to commercialization. The R&D and production strengths of Belief BioMed have been recognized by top investment institutions and enterprises. Belief BioMed has offices, research centers and manufacturing facilities in Shanghai, Hong Kong, Beijing and Suzhou China and North Carolina US.

 

Mission And Vision

Our Mission

Make gene therapy drugs available, affordable and healable.

Our Vision

To become the pioneer leading China’s gene therapy industry, to bring China’s gene therapy drugs to the world.

Key Milestones

2016

Belief BioMed core team set up

2017

High productivity cell line established

2018

CMC research and development center established, the production of hemophilia B IIT drug is completed

2019

Experimental Rodent Animal Center officially put into use, hemophilia B IIT officially launched, drug administration in primates Parkinson’s disease model, and 50L process put into production

2020

The Shanghai office, as the global headquarter and clinical research development center, officially opened; the 5,000m ² production and research base officially opened (Shanghai Minhang Science and Technology Park of ECUST); the 300m² non-human primate experiment center officially opened; hemophilia B submitted pre-IND to NMPA CDE; and two MNC License out contracts were signed; One year’s data from primate model of Parkinson’s disease; 200L manufacturing process was locked down and applied in the batch production.

2021

  • On May 14, 2021, BBM-H901as the first Hemophilia gene therapy drug and the first AAV IND gene therapy drug for rare disease intravenous administration in China, was successfully submitted and accepted by NMPA CDE. The construction of 15,000m ² commercial production and manufacturing center officially started (Shanghai Harbor Free Trade Zone Intelligent Manufacturing Park), and the 500L process put into operation.
  • On August 6, 2021, BBM-H901 injection (AAV gene therapy drug used to prevent haemophilia B in adult male patients) , was approved by National Medical Products Administration (NMPA) to enter the registered clinical trial stage.
  • On November, a subsidiary of Belief BioMed, also won the approval of special funds for the development of strategic emerging industries in Shanghai.
  • On December, Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B.

2022

  • On May, Clinical results for Belief BioMed’s developing hemophilia B gene treatment BBM-H901 published in authoritative hematology journal The Lancet Haematology.

2016

Belief BioMed core team set up

2017

High productivity cell line established

2018

CMC research and development center established, the production of hemophilia B IIT drug is completed

2019

Experimental Rodent Animal Center officially put into use, hemophilia B IIT officially launched, drug administration in primates Parkinson’s disease model, and 50L process put into production

2020

The Shanghai office, as the global headquarter and clinical research development center, officially opened; the 5,000m ² production and research base officially opened (Shanghai Minhang Science and Technology Park of ECUST); the 300m² non-human primate experiment center officially opened; hemophilia B submitted pre-IND to NMPA CDE; and two MNC License out contracts were signed; One year’s data from primate model of Parkinson’s disease; 200L manufacturing process was locked down and applied in the batch production.

2021

  • On May 14, 2021, BBM-H901as the first Hemophilia gene therapy drug and the first AAV IND gene therapy drug for rare disease intravenous administration in China, was successfully submitted and accepted by NMPA CDE. The construction of 15,000m ² commercial production and manufacturing center officially started (Shanghai Harbor Free Trade Zone Intelligent Manufacturing Park), and the 500L process put into operation.
  • On August 6, 2021, BBM-H901 injection (AAV gene therapy drug used to prevent haemophilia B in adult male patients) , was approved by National Medical Products Administration (NMPA) to enter the registered clinical trial stage.
  • On November, a subsidiary of Belief BioMed, also won the approval of special funds for the development of strategic emerging industries in Shanghai.
  • On December, Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B.

2022

  • On May, Clinical results for Belief BioMed’s developing hemophilia B gene treatment BBM-H901 published in authoritative hematology journal The Lancet Haematology.

Management Team

Xiao Xiao

Xiao Xiao

Co-Founder, Chairman and CSO, Ph.D.

Ph.D. in Molecular Biology, University of Pittsburgh

Co-founder of Bamboo / Askbio

Jane Zheng

Jane Zheng

Co-founder and CEO, Ph.D.

PhD from Institute of Neurology, Chinese Academy of Sciences

Co-founder of Genechem / Neuron Biotech

Hao Zheng

Hao Zheng

Operations, SVP

Tianjin university Pharmaceutical engineering, Bachelor

15 years of experience in pharmaceutical operation management

Hui Chen

Hui Chen

Portfolio Regulatory, VP

Fudan University, Master

19 years of experience in pharmaceutical R&D

Xia Wu

Xia Wu

Discovery, VP

Utah State University, Postdoc.

15 years of experience in AAV early discovery

Wei Jiang

Wei Jiang

Analytical Development, Senior Director

Shanghai Institute of Biochemistry and Cell Biology, CAS, Ph.D.

8 years of experience in AAV vector application

Zengmin Du

Zengmin Du

Process R&D, Senior Director

East China University of Science and Technology, Ph.D.

8 years of experience in AAV vector R&D

Philip Sin

Philip Sin

SVP

Corporate Funding and Development Department

Dartmouth College , Economics Bachelor

Senior financial services executive with 20 years of experience

Yue Dun

Yue Dun

Clinical, VP

Peking University, Master

15 years of experience in clinical development